The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategic Update

20 Feb 2007 07:00

Embargoed: 0700hrs, 20 February 2007

Akers Biosciences, Inc. Strategic Update

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products, is pleased to announce that Thomas A. Nicolette has agreed to take an executive position on the board as its new President. Moving Nicolette into an executive role, from his previous non-executive position, marks the transition of the Company from its scientific research and development roots to capitalising on its product portfolio through an emphasis on sales and marketing.

Over the last four years the Company has invested significant resources in the creation and development of platform technologies for rapid testing and screening procedures, and is now in a position to advance the market penetration of its products. Over the last twelve months the Company has made two strategic acquisitions which give it direct access to the US Military and other end users of its BreathScan, BreathAlcohol Check and LegalLimit brands of disposable alcohol testing units. Another important product for the Company is the proprietary PIFA Heparin/PF4 Rapid Assay which is currently being distributed throughout Canada, North America and, imminently, Europe. PIFA H/ PF4 is now in use or evaluation in over 780 hospitals in the US and this number is increasing on a weekly basis, whilst existing hospital customers are moving towards regular re-orders.

In order to facilitate this scale-up in production, as previously announced, the Company is designing a 43,000 sq ft manufacturing facility in Puerto Rico, expected to be on stream by November 2007, affording a substantial reduction in cost of goods manufactured as well as supply chain efficiencies.

Dr Raymond Akers, Chief Executive Officer, commented,

"Tom's appointment as President is extremely beneficial as he will now be able to give his attention, on a full time basis, to working alongside me to extract the full financial potential of our products. Having invested so much of our time and resources in creating our product line, now is the time make the transition to sales and marketing."

Thomas A. Nicolette, President, said,

"Having personally built up a number of technology based companies and progressed them into their commercial phases, I recognise that the Company is poised to enter its commercial phase fully. I am confident that my commercial experience coupled with Dr Akers' intimate understanding of the diagnostic marketplace will put us in a strong position to take advantage of the efforts of the last four years."

Enquiries:Dr. Ray Akers Chief Executive Officer, Akers 001 856 848 8698 Biosciences, Inc.

Thomas Nicolette President, Akers Biosciences, Inc. 001 856 848 8698 Ben Simons Hansard Group 020 7245 1100

Thomas A. Nicolette comes from a blue-chip business background having served as Chairman, President and Chief Executive Officer of several public companies in the USA. The largest, KNOGO Corporation, was a NYSE listed multi-national headquartered on Long Island, NY with subsidiaries, dealers and manufacturing facilities in 32 countries around the world. KNOGO, recognised as the founder of the Electronic Article Surveillance (EAS) anti-shoplifting industry, was sold to Sensormatic Electronics Corporation and is now part of Tyco International, the largest Electronic Security provider in the world.

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring rapid healthcare information directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. The Company has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com

AKERS BIOSCIENCES INC
Date   Source Headline
6th Mar 20197:00 amRNSResult of Special Meeting of Shareholders
6th Feb 20199:00 amRNSHolding in Company
6th Feb 20197:01 amRNSForm DEFA14A Filing - Additional Proxy Materials
6th Feb 20197:00 amRNSNotice of Special Meeting of Shareholders
5th Feb 20191:00 pmRNSFurther Re. Directorate Change
28th Jan 20197:00 amRNSForm PRE 14A Filing
28th Dec 20183:45 pmRNSDirector/PDMR Shareholding
19th Dec 20184:45 pmRNSIntention to Delist from AIM
18th Dec 20186:00 pmRNSIssue of Equity
10th Dec 20187:00 amRNSResult of AGM & Form 8-K Filing
26th Nov 20182:00 pmRNSFurther Re. Notice of AGM
19th Nov 20182:00 pmRNSFurther Re. Strategic Update
16th Nov 20184:00 pmRNSReverse Stock Split Update
15th Nov 20187:00 amRNSNotice of AGM
15th Nov 20187:00 amRNS3rd Quarter 2018 Results
12th Nov 20187:00 amRNSForm 8-K Filing
8th Nov 20187:30 amRNSSuspension - Akers Biosciences, Inc.
8th Nov 20187:00 amRNSTemporary Suspension of Share Trading on LSE
7th Nov 20182:50 pmRNSStrategic Update & Reverse Stock Split
2nd Nov 20184:15 pmRNSIssue of Equity - Completion & Form 8-K/A Filing
2nd Nov 201810:52 amRNSUpdate Re Issue of Equity
31st Oct 20181:35 pmRNSIssue of Equity & Form 8-K
19th Oct 20182:53 pmRNSForm 8-K Filing
19th Oct 20187:00 amRNSDirectorate Change
12th Oct 20187:00 amRNSForm 8-K/A Filing & Other Updates
8th Oct 20187:00 amRNSDirectorate Change & Other Information
13th Sep 20187:00 amRNSDirectorate Change - Form 8-K Filing
15th Aug 20187:00 amRNS2nd Quarter & H1 2018 Results
27th Jul 20183:00 pmRNSHolding(s) in Company
26th Jul 20187:30 amRNSRestoration - Akers Biosciences Inc.
26th Jul 20187:00 amRNSMailing of 2017 Annual Report
20th Jul 20183:05 pmRNSIssue of Equity
20th Jul 20183:00 pmRNSCorrection: Issue of Equity
18th Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
16th Jul 20187:03 amRNS1st Quarter 2018 Results
16th Jul 20187:02 amRNSFinal Results 2017 (Restated)
16th Jul 20187:01 amRNS3rd Quarter 2017 Results (Restated)
16th Jul 20187:00 amRNS2nd Quarter 2017 Results (Restated)
3rd Jul 201812:00 pmRNSIndependent Sales Representative Agreements - PIFA
2nd Jul 20187:30 amRNSSuspension - Akers Bioscience, Inc
29th Jun 20187:00 amRNSTemporary Suspension
21st Jun 20187:00 amRNSNotification of Class Action
20th Jun 20187:22 amRNSForm 8-K Filing
18th Jun 20187:00 amRNSForm 8-K Filing
6th Jun 20187:00 amRNSForm 8-K/A Filing
4th Jun 20187:00 amRNSForm 8-K Filing
31st May 20187:25 amRNSUpdate Re. Nasdaq Minimum Bid Price Requirement
29th May 20187:00 amRNSDirectorate Change
29th May 20187:00 amRNSWithdrawal of 510(k) Submission - Chlamydia Assay
29th May 20187:00 amRNSNotice of Form 10-Q Filing Delinquency from Nasdaq

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.